ProteoTech, Inc.
12040 115th Ave., NE
Kirkland, WA  98034

 

Office: (425) 823-0400
Fax: (425) 823-8508
E-mail: info@proteotech.com

 

Close Window

A World Leader in Therapeutics and

Diagnostics Targeting Amyloid Diseases

 

 

The world-wide number of Alzheimer's patients is expected to grow from 16 million to 21 million by 2010. The Alzheimer's disease drug market is expected to grow by 15 percent annually for the next five years. This drug market generated more than $1.3 billion in 2004 in the U.S. alone, and is expected to reach $5.5 billion by 2009.

 

The global market for Parkinson's disease drug therapies is nearly $3 billion a year and growing. This includes $720 million in the United States. Approximately one percent of the population over the age of 65 is estimated to suffer from Parkinson's disease. In the US about 1.5 million people suffer from this disease. As with Alzheimer's disease, our aging population will give rise to a steadily growing number of people who suffer from Parkinson's disease.

 

The prevalence of type 2 diabetes in the United States, Europe, and Japan continues to grow at an alarming rate. The type 2 diabetes drug market is expected to reach US $2.5 billion in 2010. ProteoTech's approach to the treatment of this disease allows us to participate in another multi-billion dollar therapeutic market.

News

November 11, 2008
ProteoTech to Present at Rodman & Renshaw's 10th Annual Healthcare Conference

 

August 07, 2008
ProteoTech's Exebryl-1® Enters Human Clinical Trials for the Treatment of Alzheimer's Disease

 

July 29, 2008
Exebryl-1® Phase I Human Clinical Trial for Alzheimer's disease commences

 

July 25, 2008
ProteoTech to present at International Alzheimer's Conference—Chicago, IL.

 

May 28, 2008
ProteoTech receives clearance from FDA to proceed with Phase I Human Clinical Trials for Exebryl-1®

 

May 15, 2008
ProteoTech receives NIH SBIR Phase II continuation award for systemic amyloidosis therapeutic research

 

April 28, 2008
ProteoTech files IND for Exebryl-1® for the treatment of mild-to-moderate Alzheimer's Disease